Circulating lipocalin‐2 as a novel biomarker for early neurological deterioration and unfavorable prognosis after acute ischemic stroke
Brain and Behavior · 2023
DOI: 10.1002/brb3.2979 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain and Behavior, 2023. Verfasst von Yi Xie und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, China. Hauptthemen laut MEDLINE: Brain Ischemia, Ischemic Stroke, Stroke. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province.
Themen: Schlaganfall
Abstract (Originalsprache)
Introduction
Lipocalin‐2 (LCN2) is an acute‐phase protein that could mediate neuroinflammation after brain injury. We aimed to evaluate if LCN2 level was associated with early neurological deterioration (END) in acute ischemic stroke patients, thus hindering clinical recovery.
Methods
We conducted a prospective study of acute ischemic stroke patients between June 2021 and February 2022. Serum LCN2 concentration was measured after admission using an enzyme‐linked immunosorbent assay. Outcomes included END and 90‐day poor functional outcome (modified Rankin Scale 3‐6). The National Institutes of Health Stroke Scale increment ≥4 points within 72 h after admission was defined as END.
Results
A total of 253 acute ischemic stroke patients (mean age, 65.2 ± 13.4 years; 64.0% male) were recruited. In the multivariate adjustment, increased serum LCN2 levels (per 1‐SD increase of LCN2) were associated with a higher risk of END (odds ratio [OR], 1.64; 95% confidence interval [CI], 1.20–2.25; p = .002) and 90‐day poor outcome (OR, 1.73; 95% CI, 1.22–2.45; p = .002). Restricted cubic splines found a linear relationship between LCN2 level and 90‐day unfavorable outcome (END, p = .001 for linearity; 90‐day poor outcome, p = .013 for linearity). Subgroup analysis further confirmed the significant association of LCN2 with clinical outcomes.
Conclusions
This study demonstrated that higher circulating LCN2 level was associated with an increased risk of early clinical worsening and 90‐day unfavorable outcomes in ischemic stroke patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, China.
- Outpatient Department, Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, China.
- Department of Neurology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China.
- Department of Neurology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.
ORCID-Profile: Yi Xie, Xiaohao Zhang
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangsu Province
Zitieren
APA
Xie, Y., Zhuo, X., Xing, K., Huang, Z., Guo, H., Gong, P., Zhang, X., & Li, Y. (2023). Circulating lipocalin‐2 as a novel biomarker for early neurological deterioration and unfavorable prognosis after acute ischemic stroke. Brain and Behavior. https://doi.org/10.1002/brb3.2979
Vancouver
Xie Y, Zhuo X, Xing K, Huang Z, Guo H, Gong P, et al. Circulating lipocalin‐2 as a novel biomarker for early neurological deterioration and unfavorable prognosis after acute ischemic stroke. Brain and Behavior. 2023. doi:10.1002/brb3.2979
BibTeX
@article{Xie2023,
author = {Xie, Yi and Zhuo, Xingfeng and Xing, Kai and Huang, Zhenqian and Guo, Hongquan and Gong, Pengyu and Zhang, Xiaohao and Li, Yun},
title = {Circulating lipocalin‐2 as a novel biomarker for early neurological deterioration and unfavorable prognosis after acute ischemic stroke},
journal = {Brain and Behavior},
year = {2023},
doi = {10.1002/brb3.2979}
}
EUVIMED